Hadoux, Julien <br/><br/>
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.  [electronic resource] 

 -  International journal of cancer  Dec 2014 
 - 2711-20 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.28913  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenal Gland Neoplasms--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Alkylating--therapeutic use<br/>Biomarkers, Tumor--genetics<br/>Brain Neoplasms--drug therapy<br/>DNA Methylation<br/>DNA Modification Methylases--genetics<br/>DNA Repair Enzymes--genetics<br/>Dacarbazine--analogs & derivatives<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Male<br/>Middle Aged<br/>Mutation--genetics<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Paraganglioma--drug therapy<br/>Pheochromocytoma--drug therapy<br/>Polymerase Chain Reaction<br/>Prognosis<br/>Promoter Regions, Genetic--genetics<br/>Retrospective Studies<br/>Succinate Dehydrogenase--genetics<br/>Survival Rate<br/>Temozolomide<br/>Tumor Suppressor Proteins--genetics